Merck's most recent trend suggests a bearish bias. One trading opportunity on Merck is a Bear Call Spread using a strike $65.00 short call and a strike $70.00 long call offers a potential 7.3% return on risk over the next 37 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $65.00 by expiration. The full premium credit of $0.34 would be kept by the premium seller. The risk of $4.66 would be incurred if the stock rose above the $70.00 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Merck is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Merck is bearish.
The RSI indicator is at 73.92 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Merck
Agilent Arm/Cell Signaling Tie for Companion Diagnostics – Analyst Blog
Thu, 15 Jan 2015 17:30:05 GMT
Healthcare Executives on a Saturday
Thu, 15 Jan 2015 15:30:00 GMT
Merck Presents Liquid Crystal Window Technology at BAU 2015
Thu, 15 Jan 2015 08:02:50 GMT
noodls – Pressemitteilung Contact News release Judith Rahner +49 6151 72-7694 January 15, 2015 • Liquid crystal mixtures from Merck enable intelligently switchable windows that reduce energy consumption • With …
Pfizer to Skip Melanoma in Bid to Join Cancer Race
Thu, 15 Jan 2015 05:01:17 GMT
Merck-BMS cancer drug rivalry heats up
Wed, 14 Jan 2015 23:01:06 GMT
AAP – Drugmaker Merck & Co is ratcheting up its race with rival Bristol-Myers Squibb Co for leadership in one of today's hottest research areas, immuno-oncology, which harnesses the immune system to fight cancer. Merck says that by midyear it will apply for approval of its melanoma drug, Keytruda, for fighting lung cancer. Merck chief executive Kenneth Frazier was to announce that Merck has more than 10 drugs in late-stage patient testing and is on track with cost-cutting and other changes in its latest restructuring program, announced in October 2013.
Related Posts
Also on Market Tamer…
Follow Us on Facebook